



Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Mr. Egbert J. Savina
Official Correspondent
LIXI, Inc.
1438 Brook Drive
DOWNS GROVE IL 60315

JAN 12 2012

Re: K820658

Trade/Device Name: Lixiscope
Regulation Number: 21 CFR 892.1650
Regulation Name: Image-intensified Fluoroscopic x-ray system
Regulatory Class: II
Product Code: OXO
Dated: April 22, 1982
Received: April 29, 1982

Dear Mr. Savina:

This letter corrects our substantially equivalent letter of May 18, 1982.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please Note: CDRH does not evaluate information related to contact liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely Yours,

A handwritten signature in black ink, appearing to read "Mary S. Pastel", with a stylized flourish at the end.

Mary S. Pastel, Sc.D.
Director
Division of Radiological Devices
Office of In Vitro Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Dear Mobile Fluoroscopic Device Manufacture:

This letter is to advise you that the FDA is in the process of updating the Product Codes for Mobile Fluoroscopic (OXO) devices to provide greater specificity regarding Mobile X-Ray devices. Product Codes, and their definitions, can be found in our classification database (<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpdc/classification.cfm>).

Mobile X-Ray devices have expanded greatly in scope since the creation of the first Mobile X-Ray devices product code, IZL, over 30 years ago: from standard mobile radiographic systems to sophisticated mobile interventional fluoroscopy devices. Because of the variety of mobile X-Ray devices currently on the market, the new product code will allow FDA to distinguish between the different types of mobile S-Ray devices marketed in the United States (U.S.), thereby allowing us to serve the Medical Imaging device industry and other stakeholders in a more clear and efficient manner.

What you should do at this time:

When preparing import paperwork, including your FDA Listing, **you must** continue to reference the “Current Product Codes” that are found on your 510(k) letter of substantial equivalence to avoid delays at the port of entry into the U.S. Do **not** use the “Planned Common Name and Planned Product Code” on any FDA Submission until the codes have been finalized for your device, and you have been **notified by FDA by receipt of a revised letter of substantial equivalence for your 510(k)(s). (Attached)**

Need Further Clarifications?

If you need further clarification on the issue or any other type of assistance in complying with FDA regulations, please contact the Division of Small Manufactures, International and Consumer Assistance, (DSMICA), by email at DSMICA@CDRH.FDA.GOV

John Stigi
Director
Division of Small Manufactures, International and Consumer Assistance
Office of Communication, Education and Radiation Programs
Center for Devices and Radiological Health
U.S. Food and Drug Administration



Memorandum

Date: November 30, 2011
From: Lauren Hefner
Subject: Regarding Product Code conversion from IZL to OXO
To: The Record

510(k) K820658, Lixiscope was originally assigned a Product Code of IZL (892.1720, mobile x-ray system). As it is a fluoroscopic device it is being reassigned to the new Product Code of OXO (892.1650, image-intensified fluoroscopic x-ray system, mobile) to distinguish it from mobile radiographic x-ray systems.

Mr. Robert J. Savini
LEXI, INC.
1438 Brook Drive
Downers Grove, Illinois 60515

(MAY 18 1982

Accession No.: 82K0234
Model: Lixiscope
Dated: 4/22/82
Received: 4/29/82

Dear Mr. Savini:

We have reviewed your Section 510(k) notification of intent to market the above device and we have determined the device to be substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments of 1976. You may, therefore, market your device subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) until such time as your device has been classified under Section 513. At that time, if your device is classified into either Class II (Standards) or Class III (Pre-market Approval), it would be subject to additional controls.

General controls presently include regulations on annual registration, listing of devices, good manufacturing practices, labeling, and the misbranding and adulteration provisions of the Act.

All regulations and information on meetings of the device classification panels, their recommendations, and the final decisions of the Food and Drug Administration (FDA) will be published in the FEDERAL REGISTER. We suggest you subscribe to this publication so that you can convey your views to FDA if you desire. Also, the FEDERAL REGISTER will notify you of any additional requirements subsequently imposed on your device. Subscriptions may be obtained from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Such information also may be reviewed in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

This letter should not be construed as approval of your device or its labeling. If you desire advice on the status of labeling for your device or other information pertaining to your responsibilities under the Act, please contact:

Medical Device Section, HPX-460
Division of Compliance
Bureau of Radiological Health, FDA
5600 Fishers Lane
Rockville, MD 20857
(301) 443-3426

Sincerely yours,

BEST AVAILABLE COPY

Walter E. Gundaker
Acting Director
Division of Compliance
Bureau of Radiological Health

FILE: 82K0234 (LEXI)

cc: Mary Jo Lyons, RMD
Kansas City DO

DPW
JSM

K820658 – LIXI, Inc.

Final: CD 11.30.2011

Div/Branch	Last Name	Date	Div/Branch	Last Name	Date
DRAD	HEFNER	12-1-11			
DRAD	Ottawa	12/1/11			